A number of signs point to some promising new and continuing trends for the biotech industry in the year ahead, observers are saying, with myriad financial opportunities available to companies and investors alike. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 22, 2025.
Makary’s vision for slimmed-down US FDA somewhat reassuring
BioWorld
Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...
Dupixent bounces back in treating hives with FDA approval
BioWorld
The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for...
Akeso scores China approval for ebdarokimab in plaque psoriasis
BioWorld
China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque...